Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 17/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12654499 | 0.89 | MEN1 (0.42) | PHGDHADORA2AKMOMEN1ALDH1A1 | |
| SCHEMBL16563324 | 0.87 | PHGDH (0.45) | PHGDHADORA2AKMO | |
| SCHEMBL17655481 | 0.85 | KMO (0.43) | ADORA2AKMOMEN1KMT2A | |
| SCHEMBL12654397 | 0.85 | FAAH (0.41) | ADORA2AKMOMEN1KMT2A | |
| SCHEMBL17655480 | 0.84 | ALOX15 (0.47) | ADORA2AKMO | |
| SCHEMBL12654396 | 0.84 | MPL (0.45) | ADORA2AKMO | |
| SCHEMBL12959004 | 0.84 | TRPA1 (0.44) | ADORA2AMEN1ALDH1A1KMT2A | |
| SCHEMBL17655327 | 0.84 | PHGDH (0.49) | PHGDHADORA2A | |
| SCHEMBL12654500 | 0.84 | CA2 (0.44) | PHGDHKMO | |
| SCHEMBL12958959 | 0.83 | FGFR4 (0.49) | PHGDHADORA2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556201-B2 | Bicyclic pyridines and analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2493888-B1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252780-A1 | BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PHGDH 1399/4885ADORA2A 688/4885KMO 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.